Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Oct 6, 2015

(R) Cantargia obtains an “Intention to Grant” notice from the European Patent Office covering the IL1RAP target for the treatment of solid tumors

Oct 5, 2015

(R) Cantargia: Grant of patent by The European Patent Office (EPO)

Aug 25, 2015

(R) Cantargia Interim Report for the period 1 Jan 2015 – 30 June 2015 available

Aug 11, 2015

(R) Data on Cantargia’s antibodies in leukemia models published in international scientific journal

Jul 3, 2015

(R) Cantargia and Glycotope Biotechnology signs production agreement for lead product candidate CAN04

Jun 26, 2015

(R) Cantargia licenses BioWa POTELLIGENT® Technology platform for production of lead product candidate

May 28, 2015

(R) Cantargia obtains “Intention to Grant” notice from the European Patent Office

May 19, 2015

(R) Cantargia Interim Report for the period 1 Jan 2015 – 31 Mar 2015 available

Apr 20, 2015

(R) Cantargia strengthens management with a Vice President Clinical Development

Mar 17, 2015

(R) First day of trading in Cantargia shares and option rights on Nasdaq First North Stockholm

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye